Semaglutide for Alcohol Use Disorder: What Research Shows

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

Can semaglutide treat alcohol use disorder? Emerging clinical research indicates that semaglutide, a GLP-1 receptor agonist, significantly reduces alcohol cravings, decreases heavy drinking days, and lowers the risk of alcohol-related hospitalizations. While currently prescribed off-label for addiction, semaglutide represents a major therapeutic breakthrough when integrated into a comprehensive, medically supervised recovery program.

Key Takeaways

• Craving Reduction: Clinical trials demonstrate that semaglutide significantly lowers the intensity of alcohol cravings and reduces the number of drinks consumed per drinking day.
• Lower Hospitalization Risk: Large-scale population studies show up to a 36% lower risk of alcohol-related hospitalizations for individuals on semaglutide compared to those not receiving the medication.
• Dopamine Regulation: Semaglutide works by modulating dopamine signaling in the brain’s reward pathways, effectively turning down the “mental noise” associated with alcohol addiction.
• Not a Standalone Cure: Medication alone is insufficient for long-term recovery. Lasting sobriety requires integrating clinical therapy, metabolic repair, and nervous system regulation.
• Off-Label Status: Semaglutide is FDA-approved for diabetes and weight management, meaning its use for alcohol use disorder is currently off-label and must be medically supervised.

Understanding Alcohol Use Disorder and the Need for New Treatments

Alcohol use disorder (AUD) remains one of the most prevalent and challenging psychiatric conditions in the United States, affecting an estimated 29 million residents [1]. Despite the severe physical, emotional, and social toll of chronic alcohol abuse, fewer than 2% of individuals with AUD receive pharmacological treatment [1].

Currently, the US Food and Drug Administration (FDA) has approved only three medications to treat AUD: disulfiram, acamprosate, and naltrexone [1]. While these medications are beneficial for some, they are far from universally effective. Many patients struggle with adherence, experience intolerable side effects, or continue to experience intense, overwhelming cravings that lead to relapse. This clinical gap has driven researchers to explore novel therapeutic pathways, leading to a groundbreaking focus on metabolic hormones and the gut-brain axis.

How Semaglutide Works on Alcohol Addiction

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally designed to treat type 2 diabetes and chronic weight management [2]. It works by mimicking the natural GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and signals satiety to the brain [2]. However, the receptors for this hormone are not confined to the digestive system.

GLP-1 receptors are highly expressed throughout key regions of the brain’s reward circuitry, including the ventral tegmental area (VTA), the nucleus accumbens, and the prefrontal cortex [2]. These are the precise pathways that control motivation, pleasure, and compulsive behavior. When a person consumes alcohol, these circuits are flooded with dopamine, creating an exaggerated reward signal that reinforces the desire to drink.

By activating GLP-1 receptors in these regions, semaglutide modulates dopamine signaling [2]. It effectively dampens the hyperactive reward response triggered by alcohol without blunting a person’s capacity to experience natural, healthy pleasures. Research on opioid cravings and stimulant dependence suggests this mechanism extends well beyond alcohol. At the same time, semaglutide influences gut-brain vagal signaling and reduces neuroinflammation, which is often elevated during chronic substance use [2]. This multi-pathway mechanism stabilizes neurochemistry, making the constant mental search for alcohol far less intense.

What the Clinical Research Shows: 2024 to 2026

The scientific evidence supporting semaglutide for alcohol use disorder has advanced rapidly from anecdotal patient reports to rigorous, large-scale clinical studies.

The 2025 JAMA Psychiatry Randomized Controlled Trial

A landmark phase 2, double-blind, randomized clinical trial published in JAMA Psychiatry in 2025 evaluated the effects of once-weekly subcutaneous semaglutide in adults with AUD [1]. Led by Dr. Christian S. Hendershot, the study randomized participants to receive either a low-dose semaglutide regimen (titrated from 0.25 mg to 0.5 mg per week) or a placebo over a nine-week period [1].

The trial yielded highly encouraging results. Semaglutide significantly reduced:
– The number of drinks consumed per drinking day [1].
– Self-reported weekly alcohol cravings [1].
– The frequency of heavy drinking days [1].

In a controlled laboratory environment where participants had free access to their preferred alcoholic beverage, those treated with semaglutide consumed approximately two fewer standard drinks (a 26-gram reduction in pure alcohol) and experienced a 57% reduction in peak breath alcohol concentration compared to the placebo group [1]. Interestingly, the medication did not significantly alter the total number of drinking days, suggesting that while semaglutide may not immediately enforce complete abstinence, it is exceptionally powerful at preventing compulsive, heavy consumption.

The 2026 Lancet Study (The SEMALCO Trial)

The clinical evidence was further strengthened by a 26-week randomized controlled trial published in The Lancet in 2026 [3]. This study investigated the efficacy of once-weekly semaglutide at a higher dose (2.4 mg) in 108 treatment-seeking adults who had both AUD and comorbid obesity [3]. All participants in both the active and placebo arms were also provided with cognitive behavioral therapy (CBT) [3].

The researchers found that participants receiving semaglutide experienced a dramatic reduction in heavy drinking days [3]. Over the course of the 26-week trial, heavy drinking days in the semaglutide group decreased from an average of 17 days per month to just 5 days [3]. In contrast, the placebo group only reduced their heavy drinking days to 9 days per month [3]. Total monthly alcohol consumption also fell significantly more in the semaglutide group, dropping by an average of 1,550 grams compared to a 1,025-gram reduction in the placebo group [3].

Clinical Endpoint (26-Week Lancet Trial)	Semaglutide 2.4 mg + CBT	Placebo + CBT
Reduction in Heavy Drinking Days	From 17 days to 5 days per month	From 17 days to 9 days per month
Decrease in Monthly Alcohol Consumption	-1,550.2 grams	-1,025.9 grams
Decrease in Mean Drinks Per Day	-3.5 units	-2.1 units
Average Body Weight Loss	-11.2 kg	-2.2 kg

Real-World Population Data: The Swedish Registry Study

To understand how these clinical findings translate to large, diverse populations, a nationwide cohort study published in JAMA Psychiatry in 2025 analyzed registry data from over 227,000 individuals diagnosed with AUD in Sweden between 2006 and 2023 [4]. The researchers compared periods when an individual was actively taking a GLP-1 receptor agonist to periods when they were not.

The analysis revealed that semaglutide use was associated with a 36% lower risk of alcohol-related hospitalizations [4]. This real-world risk reduction was substantially greater than that observed with standard, FDA-approved AUD medications like naltrexone, which showed only a 14% risk reduction in the same cohort [4]. Furthermore, semaglutide use was linked to a 32% reduction in hospitalizations for any substance use disorder, providing a strong signal that GLP-1 medications may help stabilize multiple forms of compulsive behavior [4].

Compliance and Safety: Navigating Off-Label Use

It is critical to understand that while the clinical evidence is robust, semaglutide is not currently FDA-approved for the treatment of alcohol use disorder. Its use in this context is considered off-label [2]. Off-label prescribing is a common, legal, and well-established medical practice, but it requires careful clinical oversight, detailed patient screening, and informed consent.

Semaglutide is generally well-tolerated, but it is associated with a specific side-effect profile, primarily involving the gastrointestinal system [3]. In the 2026 Lancet trial, the most common adverse events reported by participants included nausea, loss of appetite, vomiting, abdominal pain, reflux, and fatigue [3]. These side effects are typically mild to moderate and tend to resolve as the body adjusts to the medication, but they must be managed carefully by a qualified medical professional.

At Carrara Treatment, all medical protocols are designed and monitored by our experienced physicians, ensuring that any off-label use of semaglutide is safe, appropriate, and tailored to the individual’s metabolic and psychological profile.

The Carrara Approach: Why Medication Alone Is Not Enough

At Carrara Treatment, we recognize that a medication like semaglutide can be an invaluable tool in early recovery, but we firmly believe that “a pill is never the program” [2]. Semaglutide addresses addiction at the neurochemical level, turning down the constant, intrusive “mental noise” of cravings [2]. However, it cannot resolve the underlying emotional pain, unresolved trauma, or relational challenges that drive addictive behavior in the first place.

To achieve lasting, meaningful recovery, semaglutide must be integrated into a comprehensive, multi-dimensional treatment model. Under the direction of Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara utilizes a sophisticated, four-stage integration protocol that treats the whole person:

1. Stage 1: Stabilization (Weeks 0–4): The initial priority is safe, comfortable detoxification and acute medical stabilization [2]. Our medical team calms the nervous system and introduces targeted nutraceuticals, including N-acetyl cysteine (NAC) for glutamate modulation, omega-3 fatty acids for neuronal repair, and magnesium with L-theanine to support sleep and reduce anxiety [2].
2. Stage 2: Metabolic Repair (Weeks 2–12): Once stabilized, we introduce low-dose semaglutide as part of a broader metabolic recovery plan [2]. By quietening physical cravings, the medication creates the cognitive and emotional bandwidth needed for intensive clinical work, including individual psychotherapy, Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Somatic Trauma Therapy [2].
3. Stage 3: Regeneration (Months 3–6): As neurochemistry stabilizes, we focus on physical resilience and nervous system regulation through progressive strength training, cold plunge therapy, infrared sauna sessions, and guided breathwork [2].
4. Stage 4: Longevity and Thriving (Beyond 6 Months): We optimize long-term physical and mental health, focusing on hormonal balance, cardiovascular function, and personalized nutritional maintenance to ensure sobriety becomes the foundation for a vibrant, purposeful life [2].

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Is Semaglutide Right for Your Recovery?

Determining whether semaglutide is an appropriate addition to your treatment plan requires a comprehensive clinical evaluation. At Carrara, our medical team conducts detailed laboratory work, metabolic assessments, and psychiatric screenings to ensure candidacy.

This treatment may be particularly beneficial for individuals who have struggled with intense, persistent alcohol cravings, those who have experienced multiple relapses despite traditional therapies, or individuals who present with co-occurring metabolic concerns such as insulin resistance or weight gain. Newer dual-agonist medications like tirzepatide may also be considered depending on your clinical profile.

If you or a loved one is ready to explore how cutting-edge medicine and deeply personalized clinical care can support your path to lasting recovery, we invite you to take the first step.

For a confidential conversation about whether GLP-1 therapy may be appropriate for your situation, call (888) 383-5207.

Frequently Asked Questions

Can semaglutide completely stop alcohol cravings?

Semaglutide significantly reduces the intensity and frequency of alcohol cravings by modulating dopamine signaling in the brain’s reward pathways, making the desire to drink far more manageable. However, it is not a standalone cure. For long-term sobriety, semaglutide must be combined with comprehensive behavioral therapy, somatic healing, and lifestyle integration to address the underlying psychological drivers of addiction.

Is semaglutide FDA-approved for treating alcohol use disorder?

No, semaglutide is not currently FDA-approved for treating alcohol use disorder. Its use for substance cravings is strictly off-label. At Carrara Treatment, all off-label applications of semaglutide are conducted under the direct supervision of our expert medical team, led by Dr. Kenneth Spielvogel, MD, ensuring complete safety and personalized dosing.

What are the most common side effects of semaglutide during detox?

The most common side effects are mild to moderate gastrointestinal symptoms, including nausea, loss of appetite, vomiting, and abdominal discomfort. Because individuals in early alcohol recovery often have sensitive digestive systems, Carrara’s medical and culinary teams utilize slow, flexible titration schedules and customized, easily digestible gourmet meals to minimize discomfort.

References

[1] Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. doi:10.1001/jamapsychiatry.2024.4789.

[2] Carrara Treatment. GLP-1 Medications for Addiction Treatment: What the Research Shows and How Carrara Is Leading. Available at: https://carraratreatment.com/glp-1-addiction-treatment/.

[3] Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)00305-3.

[4] Lähteenvuo M, Tiihonen J, Solismaa A, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82(1):94-98. doi:10.1001/jamapsychiatry.2024.3599.